News FDA clears Roche's Enspryng for thyroid eye disease Roche has claimed US approval for Enspryng in a second indication, thyroid eye disease, that makes it a rival to drugs from Amgen and Viridian.
News Roche breast cancer drug Itovebi turned down by NICE NICE turns down NHS use of Roche's breast cancer drug Itovebi, which the company says reveals a flaw in the appraisal of combination therapies.
News Roche adds another obesity drug with $1.16bn Rona deal Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ALK7.
News Roche culls myostatin candidate from obesity pipeline Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
News Roche, Viking, and Syntis showcase obesity drug candidates A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
News Roche's IgAN hopeful sefaxersen passes phase 3 test Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.